Page 3 - Les Meilleurs doctors pour votre Une greffe de moelle osseuse - TOP 88 des médecins

Dr. Maha Yahia is a medical oncologist and hemato-oncologist. She provides assessment, diagnosis, and treatment planning. Her treatments include chemotherapy, targeted therapy, and immunotherapy. She cares for patients with breast, genitourinary, gynecologic, thoracic, gastrointestinal, and rare cancers.

Education: M.B.B.Ch, Kasr El-Aini, Cairo University (1997–2003). Master in Hemato-oncology, National Cancer Institute, Cairo University (2008). Doctoral Degree in Hemato-oncology, National Cancer Institute, Cairo University (2015).

Experience: Resident in Medical Oncology, Maadi AFMC (2005–2010). Visitor Resident, NCI Cairo (2008–2009). Consultant Assistant, Prof. Hussein Khaled Clinic (2010–2017). Specialist, International Medical Center (2011–2012), Wadi El Nile Hospital (2013–2014), and Maadi AFMC (2011–2018). Head, Clinical Research Support Team, Maadi AFMC (2016–2018). Major (2014–2016) and Lt. Colonel Doctor (2016–2018), Egyptian Armed Forces. Lecturer of Clinical Research, AFCM (2019–2021).

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.

Professor Jair Bar, MD, PhD, is a thoracic oncologist and Deputy Director of the Cancer Center at Sheba Medical Center. He leads the Thoracic Oncology Unit. He treats lung cancer, including advanced non-small cell cases. His care includes medical oncology, radiotherapy, immunotherapy, and targeted therapy.

He runs a translational research lab focused on resistance to immunotherapy. He has published on exhaled-breath cancer metabolism and on angiogenesis inhibition in lung cancer.

He has chaired the Israel Lung Cancer Group since 2003. He is a member of the Israel Society of Clinical Oncology and Radiotherapy, the American Society of Clinical Oncology, and the American Association for Cancer Research. He is board-certified in Medical Oncology and Radiotherapy Oncology. He is a Senior Lecturer at Tel Aviv University.

Dr. Iris Kventsel, MD, is a pediatric hemato-oncologist and bone marrow transplant (BMT) specialist at Sheba Medical Center. She is an attending physician in the Pediatric Hemato-Oncology and BMT Division at the Edmond and Lily Safra Children’s Hospital. Her clinical focus is pediatric sarcomas, including Ewing sarcoma, osteosarcoma, and rhabdomyosarcoma.

She provides multidisciplinary care, including transplant and cellular therapies. She also uses current chemotherapy protocols and targeted therapies for complex childhood cancers.

Her research focuses on genetic cancer predisposition, including Li-Fraumeni syndrome, and cancer susceptibility genes. She has published in pediatric oncology, stem cell biology, and surgical oncology (HIPEC). She is on the academic staff at Tel Aviv University. Education: MD, Technion; Pediatrics residency, Assaf HaRofeh; Pediatric Hemato-Oncology fellowship, Sheba.

Prof. Elad Jacoby, MD, heads the Pediatric Cell Therapy Center at Sheba Medical Center. He is the Medical Director of the Advanced Biotherapy Center. He is a pioneer of pediatric CAR T‑cell therapy in Israel. He led one of the first national leukemia programs. He has almost 20 years of clinical and research experience.

He specializes in CAR T‑cell therapy, bone marrow and stem cell transplantation, and high‑risk pediatric leukemias and lymphomas. He leads international clinical trials and has authored over 240 publications. His collaborations include Johns Hopkins Hospital and the U.S. National Cancer Institute. He is an Associate Professor at Tel Aviv University. He received his MD from Tel Aviv University, completed residency at Sheba Medical Center, and fellowships at Johns Hopkins and the National Cancer Institute. He is board‑certified in Pediatrics and in Pediatric Hematology and Oncology. He serves on the IBFM CAR T‑Cell Taskforce and the Sheba Institutional Review Board. He leads the integration of CAR T‑cell therapy with transplantation.

Le Professeur Zila Zuckerman est spécialisé(e) en hématologie et en transplantation de moelle osseuse au Centre Médical Rambam.

• Expertise en hématologie et transplantologie
• Qualifications de niveau professeur dans le domaine
• Exerce dans un centre médical de premier plan

La professeure Dina Ben-Yehuda dirige le Département d'Hématologie du Centre Médical Hadassah, où elle est pionnière dans les greffes de moelle osseuse et la thérapie génique.

• Spécialisée en diagnostic moléculaire des maladies du sang malignes
• Honorée par le « Chief of Staff Award » pour service exceptionnel
• Première femme doyenne de la Faculté de Médecine Hadassah
• Formée au Memorial Sloan-Kettering Cancer Center à New York
• Récipiendaire du prix « Healing with the Heart Award » pour les soins aux patients

Ayant réalisé plus de 3 500 greffes de moelle osseuse – le Dr Stepensky se consacre à sauver la vie d'enfants au Centre médical Hadassah.

• 20 ans d'expérience dans la greffe de moelle osseuse pédiatrique
• Reconnu par Forbes comme l'un des meilleurs médecins en 2018
• Spécialisé dans les maladies rares du cancer du sang chez les enfants
• Connu parmi les patients comme celui qui «transplante la vie»

Le Dr Irina Zaidman est spécialisée en transplantation de moelle osseuse pédiatrique au Centre médical Hadassah, avec une formation approfondie obtenue auprès des meilleures institutions mondiales.

• Fellowship en TMO pédiatrique à l'Hospital for Sick Children de Toronto
• Membre du conseil d'administration de la Société israélienne d'hémato-oncologie pédiatrique
• A publié plusieurs articles sur les transplantations de moelle osseuse pédiatriques
• Membre des sociétés européennes et américaines de TMO

Le Dr Spielberg est spécialisé en transplantation de moelle osseuse à l'Assuta Medical Center, un établissement de premier plan pour les traitements hématologiques.

• Oncohématologue axé sur la transplantation de moelle osseuse
• Exerce à l'Assuta Medical Center, réputé pour ses soins hématologiques avancés
• Dédié au traitement des affections hématologiques complexes

Dr. Hila Magen, MD, leads the Multiple Myeloma and Amyloidosis Unit at Sheba Medical Center. She is a hemato-oncologist with over 35 years of experience. She is a leading Israeli expert in multiple myeloma and plasma cell disorders.

She runs a program that provides personalized care and early access to clinical trials. This includes CAR-T therapy for high-risk and relapsed or refractory myeloma and amyloidosis. Dr. Magen is a principal investigator in point-of-care CAR-T studies. She brings new immunotherapies into routine care.

Training: Fellowships in Multiple Myeloma (UAMS) and Lymphocytic Leukemia (MD Anderson). Academic: Instructor, Tel Aviv University. Research: Author of 100+ publications, contributor to landmark myeloma studies, and reviewer for international journals.

Prof. Avichai Shimoni, MD, is Director of Bone Marrow Transplantation at Sheba Medical Center. He is a hemato-oncologist with over 30 years of experience in bone marrow transplantation, cellular therapies, and advanced blood cancer care.

He leads a high-volume program for complex, high-risk blood cancers. He performs allogeneic and autologous transplants. He also provides CAR T-cell therapy for leukemia, lymphoma, and multiple myeloma. He completed a bone marrow transplantation fellowship at MD Anderson Cancer Center.

He is Chairman of Hematology at Tel Aviv University and a Professor of Hematology. He has authored more than 250 scientific papers. His research focuses on CAR T-cell therapy and stem cell transplantation. He is often listed among Israel's Best Doctors (Forbes 2025 and 2026).

Dr. Abraham Avigdor, MD, is Director of the Institute of Hematology and Co‑Director of the Hematology & Bone Marrow Transplantation Division at Sheba Medical Center. He is an international leader in lymphoma, CAR‑T, and advanced hemato‑oncology with more than 35 years of experience. His clinical focus includes lymphomas, multiple myeloma, and complex blood cancers.

He is a pioneer in CAR‑T integration. He leads cellular therapy and bone marrow transplantation programs (autologous and allogeneic). He also advances stem cell therapies and precision diagnostics, including PET/CT‑based prognostics. His work includes immunotherapy and targeted regimens and the development of innovative, data‑driven protocols.

He collaborates with LYSA, EMCL, and international PET groups. He has authored more than 130 publications. Key roles include Founder and President of the Israeli Lymphoma Working Group, former Chair of the Israeli Lymphoma Study Group, and Senior Lecturer at Tel Aviv University. Education: MD, Ben‑Gurion University; residency, Sheba Medical Center; postdoctoral fellowship, Weizmann Institute. Awards include the Knesset Prize, the Israeli Ministry of Health Award, and the Sackler Prize.

Chef du plus grand programme italien de transplantation de moelle osseuse, réalisant plus de 90 greffes allogéniques par an au San Raffaele. Il est l'un des meilleurs spécialistes du lymphome du pays.

• Dirige l'Unité de Transplantation de Moelle Osseuse depuis 2006
• Spécialisé en hématologie et médecine interne de l'Université de Milan
• A publié plus de 70 études sur la transplantation et les cancers du sang
• Membre de la Société Européenne pour la Transplantation de Sang et de Moelle Osseuse

Le Prof. Dr. Serdar Bedii Omay a publié plus de 65 articles scientifiques sur l'hématologie et la transplantation de moelle osseuse, et possède une vaste expérience dans ce domaine.

• Formation en hématologie moléculaire à la Faculté de médecine de Mie, au Japon
• Professeur d'hématologie aux Universités techniques d'Ege et de Karadeniz
• Spécialisé en médecine interne et en hématologie depuis 1990
• Auteur de 112 communications de réunion et de 34 présentations de conférence

Directeur de l'Unité des Lymphomes à San Raffaele – le Prof. Ferreri a fondé la Fondation Italienne du Lymphome pour des études cliniques avancées.

• Directeur adjoint d'Hématologie Oncologie avec plus de 20 ans d'expérience
• Auteur de plus de 300 articles sur le traitement du lymphome
• Spécialisé dans la recherche sur les lymphomes non hodgkiniens
• Membre de l'Association Européenne d'Hématologie & de la Société Américaine d'Hématologie